KeyBanc raised the firm’s price target on ResMed (RMD) to $266 from $251 and keeps an Overweight rating on the shares following the Q1 earnings report. KeyBanc was encouraged by the broad outperformance starting fiscal 2025, especially around trends in Devices in light of ongoing GLP-1 concerns, the analyst tells investors in a research note. ResMed is also continuing to reduce debt, providing increased flexibility for capital allocation, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RMD:
- ResMed price target raised to $232 from $224 at RBC Capital
- ResMed price target raised to $283 from $280 at Baird
- Closing Bell Movers: Deckers up 12% after earnings beat
- ResMed reports Q1 non-GAAP EPS $2.20, consensus $2.04
- ResMed options imply 6.9% move in share price post-earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
